- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05962606
Safety and Efficacy of AON-D21 in Severe Community-Acquired Pneumonia.
An Exploratory, Multi-Centre, Interventional, Prospective, Randomised, Double-Blind, Placebo-Controlled Clinical Trial to Assess the Safety and Efficacy of AON-D21 in Patients With Severe Community-Acquired Pneumonia.
The goal of this clinical trial is to compare the safety and efficacy of AON-D21 versus placebo, both on top of standard of care, in patients with severe community acquired pneumonia admitted to ICU (or similar unit). The main questions to answer are:
- The safety and tolerability of AON-D21 vs placebo.
- The efficacy of AON-D21vs placebo.
- The pharmacokinetics of AON-D21.
- The pharmacodynamics of AON D21.
- To identify biomarkers for patient stratification and analyses in future trials.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This clinical trial will enroll 100 participants, randomized 2:1 (AON-D21:placebo).
Participants diagnosed with severe community-acquired pneumonia of bacterial or viral origin requiring admission to an intensive care unit or similar setting, will receive either AON-D21 or placebo intravenous infusions for up to 10 days.
In addition, participants will receive standard of care as per local guidelines.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Antonio Perez, MD
- Phone Number: +49-30-959 982-140
- Email: perez@aptarion.com
Study Contact Backup
- Name: Axel Vater, PhD
- Phone Number: +49-30-959 982-140
- Email: vater@aptarion.com
Study Locations
-
-
-
Brussels, Belgium
- Recruiting
- Cliniques Universitaires Saint-Luc
-
Contact:
- Xavier Wittebole, Prof.
-
Ottignies, Belgium
- Recruiting
- Clinique Saint Pierre
-
Contact:
- Nicolas De Schryver, Dr.
-
-
-
-
-
Argenteuil, France
- Recruiting
- Centre Hospitalier Argenteuil
-
Contact:
- Gaetan Plantefeve, Dr.
-
La Roche-sur-Yon, France
- Recruiting
- Centre Hospitalier Départemental Vendée
-
Contact:
- Jean-Claude Lacherade, Dr.
-
Limoges, France
- Recruiting
- CHU Dupuytren
-
Contact:
- Bruno Francois, Dr.
-
Melun, France
- Recruiting
- Centre Hospitalier de Melun
-
Contact:
- Mehran Monchi, Dr.
-
Nantes, France
- Recruiting
- Hotel Dieu - CHU Nantes
-
Contact:
- Gauthier Blonz, Dr.
-
Strasbourg, France
- Recruiting
- Nouvel Hôpital Civil
-
Contact:
- Ferhat Meziani, Prof.
-
Trévenans, France
- Recruiting
- Hopital Nord Franche Comte
-
Contact:
- Julio Badie, Dr.
-
-
-
-
-
Berlin, Germany
- Recruiting
- Charité - Universitätsmedizin Berlin
-
Contact:
- Martin Witzenrath, Prof.
-
-
-
-
-
Cardiff, United Kingdom
- Recruiting
- University Hospital of Wales
-
Contact:
- Matt Wise, Prof.
-
Liverpool, United Kingdom
- Recruiting
- Liverpool University Hospitals NHS Foundation Trust
-
Contact:
- Ingeborg Welters, Prof.
-
London, United Kingdom
- Recruiting
- University College London
-
Contact:
- David Brealey, Dr.
-
Reading, United Kingdom
- Recruiting
- Royal Berkshire Foundation Trust
-
Contact:
- Matthew Frise, Dr.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Community-acquired pneumonia, confirmed or suspected of bacterial or viral origin.
- Admitted to an ICU (or similar unit).
- Requiring respiratory support by HFO ≥ 30 L/min with FiO2 ≥ 30% or NIV or IMV or ECMO.
- CRP ≥ 50 mg/L.
- PaO2/FiO2 ratio ≤ 300 mmHg.
- Treatment initiation no more than 48 h after initiation of respiratory support (HFO ≥ 30 L/min with FiO2 ≥ 30%, NIV, IMV or ECMO).
- Written informed consent.
- Age ≥ 18 years to ≤ 85 years.
- Body mass index ≥ 17.5 kg/m² and ≤ 40 kg/m².
- For female participants of childbearing potential, agreement to use dual methods of contraception until Day 60.
- For male participants with female partners of childbearing potential, agreement to use barrier method of contraception until Day 60 and to refrain from donating sperm during the study and for 3 months after the last infusion.
Exclusion Criteria:
- Refractory septic shock.
- Not expected to survive 72 hours.
- Hospital-acquired or ventilator-associated pneumonia or known or suspected pneumonia due to aspiration or other physical injury or trauma or tuberculosis.
- Known or suspected hypersensitivity to AON-D21 or any components of the formulation used (e.g., PEG, mannitol or EDTA) or a history of clinically relevant allergy requiring continuous treatment, or of anaphylaxis.
- Known fibrotic lung disease, bronchiectasis or any other known severe chronic respiratory disease.
- Active malignant disease.
- Factors other than a pathogen suspected or confirmed to be causative for the respiratory insufficiency.
- Hepatocellular injury defined by an ALT or AST value ≥ 3 times the ULN. Known acute or chronic liver disease with Child-Pugh C (See Appendix 13.6.2).
- Any medical disease or condition that, in the opinion of the investigator(s), compromises the participant's safety or compromises the interpretation of the results.
- Receiving chronic immunosuppressive therapy in relevant doses.
- Known immunodeficiency disease/condition.
- Nursing and pregnant women (defined as the state after conception until the termination of gestation, screened in all women of child-bearing potential with a chorionic gonadotrophin (hCG) blood test (local laboratory).
- Current or recent participation in an investigational trial.
- Systemic treatment with any complement inhibitor.
- Known complement deficiency.
- Unlikely to remain at the investigational site beyond 96 h.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: AON-D21 plus Standard of Care
Sterile liquid formulation of AON-D21 in 4% mannitol + 0.05% EDTA in glass vials.
It will be administered intravenously, for up to 10 days plus Standard of Care therapy for severe community-acquired pneumonia as per local guidelines.
|
AON-D21 is a Pegylated L-configured aptamer that binds and thereby neutralizes the complement component C5a from activating both C5a receptors.
|
Placebo Comparator: Placebo plus Standard of Care
Sterile liquid formulation of 5% glucose solution in matched glass vials with a 1.5 mL fill volume.
It will be administered intravenously, for up to 10 days plus Standard of Care therapy for severe community-acquired pneumonia as per local guidelines.
|
Sterile liquid formulation of 5% glucose solution in matched glass vials with a 1.5 mL fill volume.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of Treatment-Emergent Adverse Events.
Time Frame: 28 days.
|
To evaluate the safety and tolerability of AON-D21 versus placebo, including the frequency, severity, and relatedness to study drug of serious and non-serious treatment-emergent adverse events (TEAEs) until Day 28.
|
28 days.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Efficacy-no longer requiring respiratory support.
Time Frame: 28 days.
|
Comparing AON-D21 vs placebo on time to no longer requiring respiratory support (defined as high-flow oxygen (HFO) ≥ 30 L/min with FiO2 ≥ 30%), non-invasive mechanical ventilation (NIV), invasive mechanical ventilation (IMV) or extracorporeal membrane oxygenation (ECMO) within 28 days.
|
28 days.
|
Efficacy-no longer requiring any organ support.
Time Frame: 28 days.
|
Comparing AON-D21 vs placebo on time no longer requiring any organ support within 28 days.
|
28 days.
|
Efficacy-time to improvement.
Time Frame: 28 days.
|
Comparing AON-D21 vs placebo on time to improvement (defined as a de-escalation in respiratory support) within 28 days.
|
28 days.
|
Efficacy-mean change in SaO2/FiO2 ratio.
Time Frame: 7 days.
|
Comparing AON-D21 vs placebo on mean change in SaO2/FiO2 ratio from Day 1 (Baseline) to Day 7.
|
7 days.
|
Efficacy-organ support-free days.
Time Frame: 28 days.
|
Comparing AON-D21 vs placebo on organ support-free days until Day 28.
|
28 days.
|
Efficacy-invasive mechanical ventilation (IMV) or extracorporeal membrane oxygenation (ECMO)-free days.
Time Frame: 28 days.
|
Comparing AON-D21 vs placebo on invasive mechanical ventilation (IMV) or extracorporeal membrane oxygenation (ECMO)-free days until Day 28.
|
28 days.
|
Efficacy-respiratory support-free days.
Time Frame: 28 days.
|
Comparing AON-D21 vs placebo on respiratory support-free days until Day 28.
|
28 days.
|
Efficacy-all-cause mortality.
Time Frame: 28 days.
|
Comparing AON-D21 vs placebo on all-cause mortality up to Day 28.
|
28 days.
|
Efficacy-all-cause mortality.
Time Frame: 60 days.
|
Comparing AON-D21 vs placebo on all-cause mortality up to Day 60.
|
60 days.
|
AUC of AON-D21.
Time Frame: 10 days.
|
Area under the concentration-time curve (AUC) over the dosing interval at steady state (AUC0-tau).
|
10 days.
|
Cmax of AON-D21.
Time Frame: 10 days.
|
Maximum concentration at steady state (Cmax)
|
10 days.
|
Cav of AON-D21.
Time Frame: 10 days.
|
Average drug concentration at steady state (Cav).
|
10 days.
|
Ctrough of AON-D21.
Time Frame: 10 days.
|
Trough concentrations (Ctrough).
|
10 days.
|
Tmax of AON-D21.
Time Frame: 10 days.
|
Time of maximum concentration at steady state (Tmax).
|
10 days.
|
Half-life of AON-D21.
Time Frame: 12 days.
|
Terminal half-life at steady state (t1/2).
|
12 days.
|
Accumulation of AON-D21.
Time Frame: 10 days.
|
Accumulation ratio for Cmax.
|
10 days.
|
Clearance of AON-D21.
Time Frame: 12 days.
|
Clearance (CL).
|
12 days.
|
Volume of distribution of AON-D21.
Time Frame: 12 days.
|
Volume of distribution (Vz).
|
12 days.
|
C5a inhibition with AON-D21.
Time Frame: 12 days.
|
To determine the C5a inhibition capacity of AON-D21 by measuring active C5a in blood using a cell-based assay.
|
12 days.
|
Procalcitonin's measurement.
Time Frame: 12 days.
|
Evolution of procalcitonin over time.
|
12 days.
|
Ferritin's measurement.
Time Frame: 12 days.
|
Evolution of ferritin over time.
|
12 days.
|
IL-6's measurement.
Time Frame: 12 days.
|
Evolution of IL-6 over time.
|
12 days.
|
C5a's measurement
Time Frame: 12 days.
|
Evolution of C5a over time.
|
12 days.
|
sC5b-9's measurement.
Time Frame: 12 days.
|
Evolution of sC5b-9 over time.
|
12 days.
|
Neutrophil elastase's measurement.
Time Frame: 12 days.
|
Evolution of neutrophil elastase over time.
|
12 days.
|
D-dimer's measurement.
Time Frame: 12 days.
|
Evolution of D-dimer over time.
|
12 days.
|
Pro-Adrenomedullin's measurement.
Time Frame: 12 days.
|
Evolution of Pro-Adrenomedullin over time.
|
12 days.
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Martin Witzenrath, MD, Critical Care Medicine. Charité Universitätsmedizin Berlin
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- S-D21-C300
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Community-acquired Pneumonia
-
GlaxoSmithKlineTerminated
-
GlaxoSmithKlineCompleted
-
GlaxoSmithKlineTerminated
-
GlaxoSmithKlineCompleted
-
Wyeth is now a wholly owned subsidiary of PfizerCompleted
-
University Medical Centre LjubljanaUniversity of Ljubljana, Faculty of MedicineUnknownCommunity Acquired Pneumonia | Ventilator Associated Pneumonia | Hospital Acquired PneumoniaSlovenia
-
Basilea PharmaceuticaCompletedCommunity-acquired Pneumonia (CAP) | Hospital-acquired Pneumonia (HAP)Bulgaria, Hungary, Georgia, Romania
-
Liverpool University Hospitals NHS Foundation TrustLiverpool School of Tropical MedicineCompletedCommunity Acquired Pneumonia | Lower Respiratory Tract Infection | Hospital Acquired PneumoniaUnited Kingdom
-
Future University in EgyptRecruitingCommunity-acquired PneumoniaEgypt
-
Nordsjaellands HospitalRecruitingCommunity-acquired PneumoniaDenmark
Clinical Trials on AON-D21
-
Aptarion Biotech AGCompleted
-
Aptarion Biotech AGCompleted
-
Shuguo Zheng, MDRecruiting